According to a news release from MD Anderson they have recently completed a study that shows that combining two separate chemotherapy agents is more effective than sequencing them one after another. The current standard of care for the cytotoxic chemotherapy agents used to treat prostate cancer is to treat men with advanced metastatic castration-resistant prostate [...]
Starting androgen deprivation therapy (ADT) to treat advanced prostate cancer is usually the start of a long treatment period that will continue for many years, actually until you die. Since our goal in cancer treatment is to make cancer a chronic illness and since prostate cancer does progress for most men in a relatively slow [...]
There was a study published in the journal Nature that described a promising new combination therapy for the treatment of men with advanced prostate cancers that are non-responsive to chemotherapy. The study is entitled "Immunosuppressive Plasma Cells Impede T-Cell Dependent Immunogenic Chemotherapy." The study was conducted at the University of California, San Diego. Prostate cancers [...]
Many men express great hesitation to move to chemotherapy with both docetaxel (taxotere) and cabazitaxel (Jevtana) because of the side effects which can include alopecia (hair loss), nail changes, neuropathy, and dysgeusia (a distortion of the sense of taste). A group of researchers hypothesized that the adverse side effects (AE) of these two chemotherapy drugs, [...]
Analysis of the PREVAIL Trial showed that Enzalutamide (Xtandi) significantly increased overall survival and radiographic progression-free survival compared with placebo in men with prostate cancer who were asymptomatic and minimally symptomatic, chemotherapy-naive and who had metastatic castration-resistant prostate cancer (mCRPC). Now, an additional analysis of the data has shown the effect enzalutamide also has on [...]